Ovarian Cancer: Evolving Concepts Around Systemic Therapy

EP. 1: GOG-0218: Frontline Bevacizumab in Ovarian Cancer

May 27th 2020

EP. 2: SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

May 27th 2020

EP. 3: PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

May 27th 2020

EP. 4: Practical Applications of PRIMA in Ovarian Cancer Management

May 27th 2020

EP. 5: PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

May 27th 2020

EP. 6: Ovarian Cancer: Factors in Deciding on Maintenance Therapy

May 27th 2020

EP. 7: Ovarian Cancer: What is the Role of HRD Testing?

May 27th 2020

EP. 8: Treating Ovarian Cancer Based on HRD Status

May 27th 2020

EP. 9: Ovarian Cancer: Updates to NCCN Guidelines

May 27th 2020

EP. 10: Ovarian Cancer: Maintenance Following Frontline Bevacizumab

May 27th 2020

EP. 11: Considerations for the JAVELIN OVARIAN 100 Study

May 27th 2020

EP. 12: Frontline Ovarian Cancer Management: Ongoing Clinical Trials

May 27th 2020

EP. 13: PARP Inhibition’s Role in Recurrent Ovarian Cancer

May 27th 2020

EP. 14: Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

May 27th 2020

EP. 15: Bevacizumab’s Role in Recurrent Ovarian Cancer

May 27th 2020

EP. 16: Recurrent Ovarian Cancer: Novel Agents Under Investigation

May 27th 2020

EP. 17: Novel Combination Strategies in Recurrent Ovarian Cancer

May 27th 2020

EP. 18: Systemic Management of Ovarian Cancer: Closing Thoughts

May 27th 2020